DENTSPLY SIRONA (NASDAQ:XRAY) Releases FY 2026 Earnings Guidance

DENTSPLY SIRONA (NASDAQ:XRAY) updated its FY 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 1.400-1.500 for the period, compared to the consensus earnings per share estimate of 1.420. The company issued revenue guidance of $3.5 billion-$3.6 billion, compared to the consensus revenue estimate of $3.6 billion.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Mizuho reduced their target price on DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. Barclays dropped their price target on DENTSPLY SIRONA from $12.00 to $9.00 and set an “underweight” rating for the company in a research report on Thursday, June 4th. BMO Capital Markets started coverage on DENTSPLY SIRONA in a report on Wednesday, July 8th. They issued a “market perform” rating and a $12.00 price objective on the stock. Citigroup began coverage on shares of DENTSPLY SIRONA in a research note on Wednesday, April 15th. They set a “sell” rating and a $10.00 target price on the stock. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of DENTSPLY SIRONA in a report on Monday. Three research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $13.46.

DENTSPLY SIRONA Stock Down 4.4%

XRAY stock opened at $13.17 on Friday. The firm has a market cap of $2.64 billion, a PE ratio of -4.18, a PEG ratio of 1.64 and a beta of 0.85. The company has a debt-to-equity ratio of 1.52, a quick ratio of 0.98 and a current ratio of 1.53. DENTSPLY SIRONA has a one year low of $9.40 and a one year high of $14.86. The firm’s 50 day moving average price is $11.74 and its 200-day moving average price is $11.89.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.35 by $0.17. DENTSPLY SIRONA had a negative net margin of 17.06% and a positive return on equity of 18.83%. The firm had revenue of $898.00 million for the quarter, compared to analyst estimates of $889.93 million. During the same period in the previous year, the firm earned $0.52 EPS. DENTSPLY SIRONA’s revenue was down 4.1% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, equities research analysts anticipate that DENTSPLY SIRONA will post 1.42 EPS for the current year.

Insider Activity

In other DENTSPLY SIRONA news, Director Brian T. Gladden acquired 9,985 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was purchased at an average price of $10.02 per share, for a total transaction of $100,049.70. Following the completion of the acquisition, the director owned 61,849 shares of the company’s stock, valued at approximately $619,726.98. This trade represents a 19.25% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Brian P. Mckeon purchased 10,000 shares of the business’s stock in a transaction on Friday, June 12th. The shares were bought at an average price of $10.12 per share, for a total transaction of $101,200.00. Following the acquisition, the director owned 10,000 shares in the company, valued at $101,200. This trade represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders acquired 35,160 shares of company stock valued at $351,179. 0.46% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On DENTSPLY SIRONA

Several hedge funds have recently modified their holdings of the stock. Daiwa Securities Group Inc. raised its position in DENTSPLY SIRONA by 2.9% in the 4th quarter. Daiwa Securities Group Inc. now owns 26,814 shares of the medical instruments supplier’s stock valued at $306,000 after buying an additional 767 shares during the last quarter. Empowered Funds LLC grew its position in shares of DENTSPLY SIRONA by 8.8% during the 1st quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock worth $244,000 after purchasing an additional 1,320 shares in the last quarter. Wilmington Savings Fund Society FSB boosted its stake in shares of DENTSPLY SIRONA by 13.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 13,055 shares of the medical instruments supplier’s stock valued at $149,000 after buying an additional 1,500 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of DENTSPLY SIRONA in the first quarter worth $26,000. Finally, Brevan Howard Capital Management LP increased its holdings in DENTSPLY SIRONA by 9.9% in the 2nd quarter. Brevan Howard Capital Management LP now owns 20,002 shares of the medical instruments supplier’s stock valued at $318,000 after buying an additional 1,800 shares during the period. 95.70% of the stock is owned by institutional investors and hedge funds.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.